May 13, 2009 (FinancialWire) — Beckman Coulter, Inc. (NYSE: BEC) said that the Federal Trade Commission has terminated its review under the Hart-Scott-Rodino Antitrust Improvement Act of 1976, of the company’s pending acquisition of Olympus Corp.’s lab-based diagnostics business.

On February 27, Beckman Coulter and Olympus said that they had entered into a definitive agreement under which Beckman Coulter will acquire the diagnostic systems portion of Olympus’ life sciences business for around $780 million.

The transaction is scheduled to close in the third quarter of 2009.

Fullerton, California-based Beckman Coulter develops, manufactures and markets products designed to automate complex biomedical tests.

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279).

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.